Estimated @-month survival rates were @ % , @ % , and @ % , respectively ( hazard ratio for death for pembrolizumab every @ weeks , @ ; @ % CI , @ to @ ; P = @ ; hazard ratio for pembrolizumab every @ weeks , @ ; @ % CI , @ to @ ; P = @ ) .